Published on

The Biopharmaceutical market is broadly divided in three Geographical clusters. All three have different characteristics in terms of potential, regulatory pathways, growth and uptake of Biosimilars.
1. USA:
a. USA is the Potential leading market for Biosimilars.
b. Biosimilar uptake is negligible in USA
c. CAGR (2005 -10) is 9%
d. There is Less clarity on regulatory pathways
2. Advanced Economies ( Europe, UK and Canada)
a. There is established frame work of regulatory pathways
b. Slow uptake of Biosimilars in these markets
c. Uptake of Biosimilars is not homogenous in all countries
d. CAGR (2005 -10) is 13-14
3. Pharmerging Markets (Brazil, China, Korea, India and Vietnam)
a. Loose regulatory pathways
b. Fast growing Biologics market
c. Uptake of Biosimilars is better than US and Advanced economies
d. The growth is the highest
Most of the immediate value creation will be from Pharmerging markets. In long term US will be the main driving worth $11 billion to US $25 in 2020 representing 4% and 10% of the total biologic market. The overall penetration of Biosimilars within the off patent biologic market is forecast to reach up to 50% by 2020, assuming a price discount of 20-30%.
Entry Barrier / Challenges
Biosimilar market is Lucrative but there are entry barriers. Some of the entry barriers have been created by existing Bio Pharmaceutical companies.
1. Manufacturer of Biologicals have started working on 2nd generation products where patents are applicable. There is motivation for clinician to use 2nd generation products as they offer better efficacy, convenience and pricing etc.
2. The investment required in developing Biosimilar facility is significantly higher than the generic drugs. It takes longer time to get the returns in case of Biologicals
3. USA is the most potential market for Biologicals and the regulatory pathways are not very clear.
4. The uptake of Biosimilars is slow and uptake is not homogenous in Europe.
5. The manufacturer of branded products use patient assistance plan. They have differential pricing for patients as per the need and requirement. They have good infrastructure and well trained team. The clinicians using these kinds of products are generally not very low in number. This creates very competitive scenario. Moreover there are safety concerns for Biosimilars at least on short term bases.
6. The manufacturers of branded products have created differentiation by using new delivery devices. There are fewer companies manufacturing these delivery devices and many of them have exclusive arrangement.
Advantage India (Biosimilars)
Worldwide, Biosimilars have expanded the market. There is advantage in setting up manufacturing plant in India
1. Low Cost
• 40 – 50% of Development cost
• 30 – 40% of Manufacturing cost
• 10 – 20% of Salaries
……….. Compared to US / EU
2. Regulatory
• International standards in Infrastructure & Mfg.
• Understanding of Biosimil

Published in: Health & Medicine, Business
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • It is not mediatory to do the comparative study in India. Toxicity study is also not required while doing preclinical study
  • Stage 3, toxicity study is must. Stage 4. There has to comparative study with the brand which is available in Europe. Additionally, immunogenicity test is required in Europe. Phase 3 added by 6 monthsYou need to fix up centers in advanceReview process is one yearThere is proper scientific advisory – you need to go to Scientific advisory before conducting phase 1 and phase 3 trial
  • Biosimilars

    1. 1. Biosimilars MarketPraveen Sikri1
    2. 2. Potential of BiopharmaceuticalsBiopharmaceuticals will continue to outperform• Address the clinical need which is unmatched by conventional therapies• At some point, patent will expire and potential of a sizeable market will attractgeneric companies• Opportunity for significant and sustained cost reduction in health care system.– Advanced Markets• Limited Economic Growth, Treatment cost, Cost of BiologicTherapies, lucrative source of saving on drug expenditure after 2015– Pharmerging Markets ( Brazil, India and China)• There is need to broaden health care coverage to large population groupagainst limited budget and growing demand for innovative drugs• Key driver for growth, attracting foreign capital by creating manufacturingand R&D centers of excellence.2
    3. 3. Potential of BiopharmaceuticalsBiopharmaceuticals will continue to outperform• Since the origin in 1980, biologics have prospered into a US$138Billion Market (2010)– Major Launches are Insulin, HGH, EPO, G CSF and MAbs– Currently accounting for 16% of global pharmaceuticalexpenditure• Top selling products includingHerceptin, Embrel, Humalog, Mabthera, Remicade and Arnacep aredue to lose patent protection over the next five years.• Key therapy areas are Cancer, Diabetes and RA3
    4. 4. 4
    5. 5. 5
    6. 6. Overview of Biosimilars Market –Cancer, Diabetes and RA6
    7. 7. Challenges• Sophisticated defensive tactics• Second-generation products• Capital investment• Post-approval safety monitoring• European guidelines• Brand development• Relative safety and efficacy of Biosimilars• Improved delivery devices• Regulatory pathway in the USA• EU generic and biopharmaceutical markets are not yet homogenous.• Price competition• Originator products’ pricing strategies• Time7
    8. 8. Time Lines – Indian Market1• Clone Development : 1 to 1.5 Years2• Process Development : 1- 2 Years3• Pre Clinical Study : 6 Months4• Short Phase 3 Study : (Indication and treatmenttype) : 1 Year5• Approval for Marketing : 3 Month to 1 Year8
    9. 9. Time Lines – Europe1• Clone Development : 1 to 1.5 Years2• Process Development : 1- 2 Years3• Pre Clinical and Toxicity study : 1 year to 1.5Years4• Phase 3 Study : (Indication and treatment type) :1.5 - 2 Year5• Approval for Marketing : 1 – 1.5 Years9
    10. 10. 2020 Out Look• Number of Differential factor will impact value creationin three Geographical Cluster– Regulatory Pathways– Speed of Intake• Most of the Immediate value creation will be fromPharmerging markets• In long term, US will be the main driving worth US $ 11Billion –US$ 25 in 2020 representing 4% and 10% ofthe total Biologic Market• The overall penetration of Biosimilars within the offpatent biologic market is forecast to reach up to 50%by 2020, assuming a price discount of 20 – 30%10Source IMS Health
    11. 11. Out Look 202011
    12. 12. Key Drivers• US Uptake– Regulators favoring innovator companies will drive down• Pharmerging Market– Any shortfall in quality standard can drive down• Europe– Late adopters major EU markets such as Spain and Italy– Physician resistance can drive down• Technology– Higher complexity of future Bio Products• Volume Effect12
    13. 13. Volume Effect13
    14. 14. 14
    15. 15. Bio Pharma in India - Hope or Hype• Worlds’ 2nd biggest supplier of childhoodvaccines• Worlds’ 4th biggest supplier of Pharmaceuticals• 3rd in Asia-Pacific (160 biotech Cos >Japan, Taiwan or Korea)• India is among TOP 11 World biotech powers• Grown by 74% in the last 2 years, 39% last year• Largest number of US-FDA-approved plants (80)outside USA• R&D spend increasing by 36% YTY15
    16. 16. ADVANTAGE INDIA(for Biosimilars)• Low Cost– 40 – 50% of Development cost– 30 – 40% of Manufacturing cost– 10 – 20% of Salaries……….. compared to US / EU• Regulatory– International standards in Infrastructure & Mfg.– Understanding of Biosimilars– Monographs in Indian Pharmacopoeia• Clinical Trial– Speedier recruitment– Vast pool of treatment naïve patients• Other– English language– IT support– Freedom to operate16
    17. 17. Indian Market17
    18. 18. 18Source :India Brand
    19. 19. The Way Forward – Indian Biosimilars19Source :India BrandEquity
    20. 20. Conclusion• Companies likely to succeed in the Biosimilars marketneed to have an appropriate marketing structure aswell as the financial resources to develop the productsand to accept higher upfront risks indevelopment, commercialisation and capitalinvestment, a major shift in skills for most genericplayers.• This skills shift means that Biosimilars players will needto evaluate their strategic options and to adoptdifferent business models and skill sets to conventionalgenerics companies. This is new territory for mostgeneric players and the likely commercial rewards ofentering most Biosimilars markets, in the short-term atleast, will probably be small…..20
    21. 21. ThanksPraveen SikriManaging PartnerIndian Pharma